This is what he actually said: “Having three products in late phase (trials) reduces the risk. That gives us multiple shots on goal for success,” Dr Itescu said. “They are not all going to work necessarily, but you only need one to make it through ... and you have a successful biopharma company.”
It's called stating the bleeding obvious. Rather than reading it as "a huge backwards step" an informed investor would understand that it's what makes Mesoblast very attractive.
This is what he actually said: “Having three products in late...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
98.0¢ |
Change
0.010(1.03%) |
Mkt cap ! $1.118B | |||
| Open | High | Low | Value | Volume |
| 96.0¢ | 99.0¢ | 95.5¢ | $5.286M | 5.409M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 91218 | 98.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.0¢ | 63577 | 4 |
View Market Depth
| Last trade - 16.10pm 27/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |